Noboru Nakaigawa

4.9k total citations
127 papers, 3.3k citations indexed

About

Noboru Nakaigawa is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Surgery. According to data from OpenAlex, Noboru Nakaigawa has authored 127 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Pulmonary and Respiratory Medicine, 42 papers in Molecular Biology and 37 papers in Surgery. Recurrent topics in Noboru Nakaigawa's work include Renal cell carcinoma treatment (60 papers), Renal and related cancers (29 papers) and Bladder and Urothelial Cancer Treatments (24 papers). Noboru Nakaigawa is often cited by papers focused on Renal cell carcinoma treatment (60 papers), Renal and related cancers (29 papers) and Bladder and Urothelial Cancer Treatments (24 papers). Noboru Nakaigawa collaborates with scholars based in Japan, United States and Poland. Noboru Nakaigawa's co-authors include Yoshinobu Kubota, Masahiro Yao, Takeshi Kishida, Yoji Nagashima, Berton Zbar, Hitoshi Ishiguro, Yasuhide Miyoshi, Laura S. Schmidt, Gregor Weirich and Hiroji Uemura and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Noboru Nakaigawa

119 papers receiving 3.3k citations

Peers

Countries citing papers authored by Noboru Nakaigawa

Since Specialization

Citations

This map shows the geographic impact of Noboru Nakaigawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noboru Nakaigawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noboru Nakaigawa more than expected).

Fields of papers citing papers by Noboru Nakaigawa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noboru Nakaigawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noboru Nakaigawa. The network helps show where Noboru Nakaigawa may publish in the future.

Co-authorship network of co-authors of Noboru Nakaigawa

This figure shows the co-authorship network connecting the top 25 collaborators of Noboru Nakaigawa. A scholar is included among the top collaborators of Noboru Nakaigawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noboru Nakaigawa. Noboru Nakaigawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cribriform pattern and IDC ‐P in prostate biopsies: prognostic relevance and reporting in metastatic disease 2025 ·The Journal of Pathology Clinical Research ·Yoichiro Okubo, Rika Kasajima, Shinya Sato, (unknown), (unknown), (unknown), (unknown), (unknown), Emi Yoshioka, Kota Washimi, (unknown), Yukihiko Hiroshima, Noboru Nakaigawa, Hiroto Narimatsu, Takeshi Kishida, Tomoyuki Yokose, (unknown)	0
2	Short-term outcomes of triplet therapy in metastatic hormone-sensitive prostate cancer in older adults: a retrospective, single-center real-world cohort study 2025 ·International Urology and Nephrology ·Keisuke Usui, Hiroyuki Kubo, Takahiro Μatsumoto, (unknown), (unknown), Takeshi Kishida, Noboru Nakaigawa	1
3	C-reactive Protein Is a Prognostic Factor for Survival in Metastatic Upper Tract Urothelial Carcinoma Patients Receiving Pembrolizumab 2024 ·In Vivo ·(unknown), (unknown), (unknown), Kimitsugu Usui, (unknown), Noboru Nakaigawa, Takeshi Kishida	1
4	Real-World Data on the Effectiveness of Microporous Polysaccharide Hemospheres for Allowing Even Novice Surgeons to Perform Robot-Assisted Radical Prostatectomy Safely 2023 ·SHILAP Revista de lepidopterología ·(unknown), Tomoyuki Tatenuma, (unknown), (unknown), Yusuke Ito, Hisashi Hasumi, Narihiko Hayashi, Noboru Nakaigawa, Kazuhide Makiyama	1
5	Cabozantinib in advanced renal cell carcinoma: A phase II, open‐label, single‐arm study of Japanese patients 2020 ·International Journal of Urology ·Yoshihiko Tomita, Katsunori Tatsugami, Noboru Nakaigawa, Takahiro Osawa, Mototsugu Oya, Hiro‐omi Kanayama, Chihiro Kondoh, Naoto Sassa, Kazuo Nishimura, Masahiro Nozawa, Naoya Masumori, Yasuhide Miyoshi, Shingo Kuroda, Shingo Tanaka, Akiko Kimura, Satoshi Tamada	22
6	The Pretherapeutic Neutrophil-to-Lymphocyte Ratio for Docetaxel-Based Chemotherapy Is Useful for Predicting the Prognosis of Japanese Patients with Castration-Resistant Prostate Cancer 2019 ·BioMed Research International ·Tomoyuki Tatenuma, Takashi Kawahara, Narihiko Hayashi, Hisashi Hasumi, Kazuhide Makiyama, Noboru Nakaigawa, Takeshi Kishida, Yasuhide Miyoshi, Masahiro Yao, Hiroji Uemura	5
7	Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis 2019 ·World Journal of Urology ·Narihiko Hayashi, Kimito Osaka, (unknown), Hisashi Hasumi, Kazuhide Makiyama, Keiichi Kondo, Noboru Nakaigawa, Masahiro Yao, Yuki Mukai, (unknown), Shoko Takano, Eiko Ito, (unknown), Izumi Koike, Masaharu Hata, Masataka Taguri, Yasuhide Miyoshi, Koji Izumi, Takashi Kawahara, Hiroji Uemura	13
8	Primary amelanotic malignant melanoma of the male urethra with inguinal lymph node metastasis successfully controlled by nivolumab: A case report 2018 ·Urology Case Reports ·Takashi Tokita, Takashi Kawahara, Yusuke Ito, (unknown), Koichi Abe, (unknown), Futoshi Sano, (unknown), (unknown), Yasushi Yumura, Noboru Nakaigawa, Masahiro Yao, Hiroji Uemura, Hidefumi Wada, Yukio Tsuura, Kazuki Kobayashi	10
9	PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer 2018 ·BMC Urology ·Takashi Kawahara, Yukari Ishiguro, Shinji Ohtake, Ikuma Kato, Yusuke Ito, Hiroki Ito, Kazuhide Makiyama, Keiichi Kondo, Yasuhide Miyoshi, Yasushi Yumura, Narihiko Hayashi, Hisashi Hasumi, Kimito Osaka, (unknown), Koji Izumi, Jun‐ichi Teranishi, Hiroji Uemura, Masahiro Yao, Noboru Nakaigawa	44
10	Fluorescent Light-Guided Cystoscopy with 5-ALA Aids in Accurate Surgical Margin Detection for TURBO: A Case Report 2018 ·Case Reports in Oncology ·(unknown), Takashi Kawahara, Shinji Ohtake, (unknown), Shinnosuke Kuroda, Noboru Nakaigawa, Koji Izumi, Yasuhide Miyoshi, Kazuhide Makiyama, Masahiro Yao, (unknown), Yoshiaki Inayama, (unknown), Hiroji Uemura	0
11	Complete Response to Sorafenib Rechallenge in a Patient with Metastatic Renal Cell Carcinoma 2017 ·Case Reports in Oncological Medicine ·(unknown), Noboru Nakaigawa, Kazuki Kobayashi	1
12	Comparison of 11C-4DST and 18F-FDG PET/CT imaging for advanced renal cell carcinoma: preliminary study 2016 ·Abdominal Radiology ·Ryogo Minamimoto, Noboru Nakaigawa, Yoji Nagashima, Jun Toyohara, Daiki Ueno, (unknown), Kazuhiko Nakajima, Masahiro Yao, Kazuo Kubota	10
13	Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer 2011 ·Cancer Science ·Shingo Kato, Kensuke Kubota, Takeshi Shimamura, Yoshiyasu Shinohara, Noritoshi Kobayashi, Seitaro Watanabe, Masato Yoneda, Masahiko Inamori, Fumio Nakamura, Hitoshi Ishiguro, Noboru Nakaigawa, Yoji Nagashima, Masataka Taguri, Yoshinobu Kubota, Yoshio Goshima, Satoshi Morita, Itaru Endo, Shin Maeda, Atsushi Nakajima, Hitoshi Nakagama	51
14	Impact of maximum Standardized Uptake Value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report 2010 ·BMC Cancer ·(unknown), Ryogo Minamimoto, Masahiro Yao, Kazuhide Makiyama, Takayuki Murakami, Futoshi Sano, Narihiko Hayashi, Ukihide Tateishi, (unknown), Takeshi Kishida, Takeshi Miura, Kazuki Kobayashi, Sumio Noguchi, Tomio Inoue, Yoshinobu Kubota, Noboru Nakaigawa	73
15	A CASE OF CYTOMEGALOVIRUS COLITIS DURING STANDARD CHEMOTHERAPY FOR TESTICULAR CANCER 2008 ·The Japanese Journal of Urology ·Narihiko Hayashi, (unknown), Futoshi Sano, Kazuhide Makiyama, Noboru Nakaigawa, Yoshinobu Kubota	2
16	Improvement on parenchymal suturing technique in laparoscopic partial nephrectomy 2008 ·International Journal of Urology ·Kazuhide Makiyama, Noboru Nakaigawa, Yasuhide Miyoshi, Takayuki Murakami, Masahiro Yao, Yoshinobu Kubota	9
17	Expression of Adipose Differentiation-Related Protein: A Predictor of Cancer-Specific Survival in Clear Cell Renal Carcinoma 2007 ·Clinical Cancer Research ·Masahiro Yao, Ying Huang, (unknown), Kéiko Hattori, Takayuki Murakami, Noboru Nakaigawa, Takeshi Kishida, Yoji Nagashima, Yoshinobu Kubota	57
18	Vascular Cell Adhesion Molecule 1 Predicts Cancer-Free Survival in Clear Cell Renal Carcinoma Patients 2006 ·Clinical Cancer Research ·(unknown), (unknown), Kéiko Hattori, Ying Huang, Futoshi Sano, Takayuki Murakami, Noboru Nakaigawa, Takeshi Kishida, Yoshinobu Kubota, Yoji Nagashima, Masahiro Yao	37
19	Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and prostate cancer cells 2005 ·Cancer Research ·Hiroji Uemura, Hitoshi Ishiguro, Noboru Nakaigawa, Yoji Nagashima, Yoshinobu Kubota	1
20	Antiproliferative Efficacy of Angiotensin II Receptor Blockers in Prostate Cancer 2005 ·Current Cancer Drug Targets ·Hiroji Uemura, Noboru Nakaigawa, Hitoshi Ishiguro, Yoshinobu Kubota	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact